D
Omeros Corporation OMER
$6.70 -$0.08-1.18% NASDAQ
Recommendation
Prev Close
$6.78
Volume
388,637
Avg Vol (90D)
737,203
Market Cap
$393.67M
Dividend & Yield
--
52-Week Range
$2.97 - $13.60
P/E (TTM)
--
EPS (TTM)
-$2.70
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
D. Boral Capital Reaffirms Buy Rating for Omeros (NASDAQ:OMER)
4/13/2025 - MarketBeat
Omeros (OMER, $6.73) RSI Indicator left the oversold zone on April 11, 2025
4/12/2025 - Tickeron - Stocks
Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight
4/11/2025 - Benzinga
Omeros (OMER, $5.86) RSI Indicator left the oversold zone on April 10, 2025
4/11/2025 - Tickeron - Technical Analysis
Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros' ...
4/10/2025 - GuruFocus
Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros' ...
4/10/2025 - GuruFocus
Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros Proprietary OncotoX-AML Clinical Program
4/10/2025 - Business Wire
Omeros (OMER, $6.5) RSI Indicator left the oversold zone on April 09, 2025
4/10/2025 - Tickeron - Stocks
Omeros (NASDAQ:OMER) Downgraded by StockNews.com to Sell
4/10/2025 - MarketBeat
See How Omeros Corp Ranks Among Analysts' Top Picks With Strong Buyback Activity
4/9/2025 - The Online Investor
Omeros (OMER, $6.03) price may climb as it broke lower Bollinger Band on Apr 08, 2025
4/9/2025 - Tickeron - Stocks
Sum Up The Pieces: UWM Could Be Worth $39
4/9/2025 - ETF Channel
Omeros Corporation To Introduce Its Proprietary T-CAT Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases
4/8/2025 - Business Wire
Omeros FY2025 EPS Estimate Decreased by Cantor Fitzgerald
4/6/2025 - MarketBeat
Omeros (OMER, $7.06) RSI Indicator left the oversold zone on April 04, 2025
4/5/2025 - Tickeron - Stocks
Omeros (NASDAQ:OMER) Shares Up 9.2% - Time to Buy?
4/4/2025 - MarketBeat
Omeros (NASDAQ:OMER) Upgraded to Hold at StockNews.com
4/4/2025 - MarketBeat
Needham & Company LLC Reiterates "Hold" Rating for Omeros (NASDAQ:OMER)
4/3/2025 - MarketBeat
Omeros Co. (NASDAQ:OMER) Receives Consensus Rating of "Moderate Buy" from Brokerages
4/3/2025 - MarketBeat
Omeros (NASDAQ:OMER) Raised to Hold at StockNews.com
4/3/2025 - MarketBeat
Omeros (NASDAQ:OMER) Trading 9.2% Higher - Time to Buy?
4/2/2025 - Ticker Report
Omeros (NASDAQ:OMER) Announces Quarterly Earnings Results
4/2/2025 - MarketBeat
Omeros (NASDAQ:OMER) Given "Buy" Rating at D. Boral Capital
4/2/2025 - MarketBeat
Omeros (OMER, $7.91) Stochastic Oscillator left the oversold zone on April 01, 2025
4/2/2025 - Tickeron - Technical Analysis
Omeros (OMER, $7.91) Moving Average Convergence Divergence (MACD) Histogram turned negative on April 1, 2025
4/2/2025 - Tickeron - Technical Analysis
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$168.31M
EBIT (TTM)
-$169.26M
Net Income (TTM)
-$156.82M
Balance Sheet
Total Assets (Q)
$277.08M
Total Debt (Q)
$423.28M
Total Liabilities (Q)
$459.69M
Book Value Per Share (Q)
-$3.15
Cash Flow
Cash from Operations (TTM)
-$119.82M
Cash from Investing (TTM)
$47.26M
Cash from Financing (TTM)
$66.98M
Net Change in Cash (TTM)
-$5.58M
Filings
Filing Date
Monday, March 31, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 12 and 16 (est)
Price History
Loading...
Beta
2.52
7-Day Total Return
3.08%
30-Day Total Return
-12.53%
60-Day Total Return
-25.64%
90-Day Total Return
-42.29%
Year to Date Total Return
-31.91%
1-Year Total Return
108.72%
2-Year Total Return
8.94%
3-Year Total Return
42.86%
5-Year Total Return
-53.86%
52-week Low
Apr 25, 2024 - $2.97
52-week High
Dec 19, 2024 - $13.60
Valuation
Market Cap
$393.67M - Small Cap
Enterprise Value
$726.82M
Price/Sales (TTM)
--
Price/Book (Q)
-2.16
Dividends and Shares
Shares Outstanding
57.99M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.omeros.com
Phone Number
206 676 5000
Address
The Omeros Building
Seattle, WA 98119
Country
United States
Year Founded
1994
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic... more
NASDAQ 04/21/2025 4:00PM Eastern Quotes delayed